Geranylgeraniol — The Mevalonate Pathway Rescuer

Geranylgeraniol (GG) is an endogenous isoprenoid synthesized via the mevalonate pathway. It serves as an essential building block for the biosynthesis of Coenzyme Q10 (CoQ10), menaquinone-4 (Vitamin K2), and dolichol. GG is also required for the prenylation (geranylgeranylation) of small GTPases like Rho and Rab, which are critical for intracellular signaling, protein trafficking, and muscle cell survival. Statins inhibit HMG-CoA reductase upstream in the mevalonate pathway, depleting GG and downstream metabolites, which is a primary mechanism underlying statin-induced myopathy. Supplementation with GG bypasses this blockade, restoring protein prenylation and CoQ10 synthesis.

Human trials are limited but emerging. An 8-week dose-escalation trial (150–300 mg/day) in healthy adults demonstrated safety with no adverse changes in blood chemistry or hematology, and an exploratory subgroup analysis suggested potential benefits for testosterone levels in men with lower baseline levels. Trials investigating its efficacy for statin-associated myopathy are currently underway.

150–300 mg/day is the most studied range in human trials. It is typically taken orally. For statin users, some protocols suggest concurrent use to mitigate myopathy, though definitive human dose-finding for this specific indication is still ongoing.

Generally well-tolerated in human trials up to 300 mg/day with no significant adverse effects on comprehensive metabolic panels or complete blood counts. Long-term safety data in humans is lacking. Due to its role in the mevalonate pathway, theoretical interactions exist with statins and bisphosphonates, though it is often investigated specifically to rescue the adverse effects of these drugs.

Key Papers